Kornimate/medical-research-clean huggingface dataset:
novel mri strategies as a non-invasive biomarker in women with uterine fibroids

Conditions: Fibroid; Leiomyoma

Summary: fibroids are present in up to 80% of women of reproductive age. associated heavy menstrual bleeding is often an indication for surgery. at present there are no long-term medical treatments for fibroids. there is an unmet need for a pharmacologic agent able to reduce excessive bleeding and other symptoms associated with increased uterine volume, which could prevent or significantly delay surgery without causing significant unwanted hypoestrogenic side effects and allow preservation of fertility. the purpose of this study is to investigate and validate novel mr imaging as a non-invasive biomarker for monitoring responses to medical interventions aimed at reduction of excessive menstrual bleeding and decrease in uterine/ fibroid volume. mr imaging is non-invasive, does not involve ionizing radiation and new techniques have the potential to resolve tissue detail to near cellular level. the investigators are aiming to establish the feasibility and reproducibility of novel mr imaging techniques in the evaluation of treatment response in women with fibroids and to provide mechanistic information on whether the reduction in blood flow of uterine/fibroid vasculature in the shrinkage of fibroids is dependent upon subjects being hypoestrogenic.


Eligibility criteria:
inclusion criteria: * age\>18 years * scheduled for hysterectomy with a fibroid uterus * at least one intramural non-pedunculated, submucosal or subserous fibroid(\>2cm) or multiple small fibroids (uterine volume\>200cm3) * ability to understand and willingness to sign consent form * normal smear within 3 years exclusion criteria: * pregnant or lactating * contra indication to mri * unable to tolerate supine position * diabetes and/or renal or hepatic impairment * contra indication to any of the study medications including gadolinium, mri contrast

Keywords: mti fibroids novel mr imaging techniques
evaluation of factors ii, vii, ix, x, and proteins c and s, following high-dose vitamin k supplementation

Conditions: Thrombosis

Summary: the purpose of this study is to evaluate factor levels of the pro coagulant factors ii, vii, ix, x, and the anticoagulant factors protein c and s in healthy volunteers during the intake of elevated levels of vitamin k in order to investigate whether there is any evidence that high dose vitamin k intake increases plasma coagulation factor activity.

1. recruit 8 male healthy individuals with no prior history of arterial or venous thrombosis (2 each from each of the following age ranges: 20-34, 35-49, 50-64, \>65). 2. visit 1: measure baseline activity levels of factor ii, factor vii, factor ix, factor x, and levels of d-dimer, tat complexes, protein c and s activities. also measure thrombin generation potential. collaboration with a research laboratory will be sought to also determine factor viia levels. 3. visit 2: measure activity of factor ii, factor vii, factor ix, factor x, levels of d-dimer, tat complexes, protein c and s activities and thrombin generation potential at the end of the 2 week period. 4. have each individual consume 20 mg of vitamin k2 orally per day for two weeks. 5. visit 3: measure factor ii, factor vii, factor ix, factor x, d-dimer, tat complexes, protein c and s activities and thrombin generation potential at the end of the 2 week period. 6. total length of study is 4 weeks. 7. analyze the data sets for changes in levels / activities due to vitamin k supplementation.

Eligibility criteria:
inclusion criteria: * healthy adult male exclusion criteria: * prior history of arterial or venous thrombosis

Keywords: vitamin k thrombosis
tumor exosome liquid biopsy strategy to diagnose pancreatic cancer

Conditions: Pancreatic

Summary: this is an observational study of patients diagnosed with pancreatic cancer by pathology, with a control group of patients with pathology suggestive of benign pancreatic lesions and normal subjects, and the diagnostic ability of exosomes to identify patients with pancreatic cancer was assessed through the detection of exosomes in the peripheral blood.


Eligibility criteria:
inclusion criteria: diagnosis of pancreatic cancer confirmed by imaging (case) diagnosis of chronic pancreatitis confirmed by imaging (hospital control) exclusion criteria: the pathology diagnosis and imaging does not matched patients with other malignant tumors patients with other severe systemic diseases
prospective single-center study about the use of ctdna in the management of patients with tumors of the gastrointestinal tract

Conditions: Pancreas Cancer; Colon Cancer; Biliary Tract Cancer

Summary: this study will evaluate the use of ctdna in the clinical management of patients with tumors of the gastrointestinal tract.

this is a a prospective observational single-center study; it is a spontaneous study, not sponsored by pharmaceutical companies, and does not involve the use of experimental drugs. the study involves a collection of data, carried out while protecting the anonymity and personal information of individual patients suffering from neoplasms of the gastrointestinal tract, the execution of peripheral blood samples and the collection of faecal material at pre-determined times -points. circulating biomarkers (as ctdna) will be evaluated in these samples, in order to optimize both the diagnostic and therapeutic processes of patients with tumors of the gastrointestinal tract.

Eligibility criteria:
inclusion criteria: * age \>18 years * ps ecog \<2; * histological diagnosis of gastrointestinal cancer: esophageal, gastric, intestinal, pancreatic, biliary tract neoplasms; * radiological evidence of resectable/locally advanced/metastatic disease on the date of signing the written informed consent; * adequate organ and function; * availability of tumor histological material. exclusion criteria: * no histological diagnosis of neoplasia of the gastrointestinal tract. * no written informed consent.
safety, pharmacodynamics (pd), pharmacokinetics (pk) study of shp141 in 1a, 1b, or 2a cutaneous t-cell lymphoma (ctcl)

Conditions: Lymphoma, T-Cell, Cutaneous

Summary: the purpose of this study is to investigate the safety and tolerability of topical shp141 applied directly to skin lesions in patients with stage ia, ib, or iia cutaneous t-cell lymphoma. this study will also investigate the effect of shp141 on skin lesions in patients with stage ia, ib, or iia ctcl.


Eligibility criteria:
inclusion criteria: * histopathologically confirmed ctcl; a documented verifiable biopsy report is required. * documented clinical stage ia, ib, or iia ctcl. * skin lesion involvement of at least 3% of bsa accessible for topical application of study drug and biopsy. * ecog performance status of 0-2. exclusion criteria: * ctcl with histologic evidence of folliculotropic variant or large cell transformed ctcl. * severe pruritus requiring systemic or topical treatment. * palpable lymph node ≥1.5 cm in diameter (unless the lymph node has been biopsied and has been designated as stage ia-iia disease). * coexistent second malignancy or history of prior solid organ malignancy within previous 5 years (excluding basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix (cin 3), papillary or follicular thyroid cancer that has been treated curatively, or prostate cancer that has been treated curatively). * any prior history of a hematologic malignancy (other than ctcl). * history of or current major renal, hepatic, gastrointestinal, pulmonary, cardiovascular, genito-urinary or hematological disease, cns disorders, infectious disease or coagulation disorders as determined by the investigator. * evidence of active hepatitis b or c or hiv. * circulating atypical cells \>5%

Keywords: ctcl cutaneous t-cell lymphoma
comparison of mccoy laryngoscope and c-mac d-blade video laryngoscope in obese patients

Conditions: Obesity

Summary: obesity is associated with difficult intubation rate of 30%, and this study was performed to compare the use of mccoy laryngoscope and c-mac d-blade video laryngoscope for intubation in obese patients. a total 104 patients with body mass index (bmi) ≥ 35kg/m² scheduled for general anesthesia were randomly assigned to be intubated with mccoy laryngoscope or c-mac d-blade video laryngoscope. the primary outcome was intubation time, and secondary outcomes were mask ventilation scale, intubation difficulty scale (ids), percentage of glottis opening (pogo) score, and hemodynamic variables including mean arterial pressure, heart rate and saturation.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical status of i-ii patients with bmi ≥ 35 kg/m² scheduled for general anesthesia exclusion criteria: * patients with tracheal diseases, sore throat, neck pain and loose tooth.

Keywords: obesity intubation laryngoscopes
helium neon laser versus gallium arsenide laser

Conditions: Venous Leg Ulcer

Summary: there will be different effects for different laser wavelengths in treatment of venous ulcer.

the cost of treating venous ulcer can vary within wide limits and depends on the technology used. in the countries of the european community, the closure of one ulcer as an outpatient procedure costs 800-1500 euros, and supporting anti-relapse treatment makes 100-150 euros per month. in the united states, for closure of venous ulcer within 3 months, direct medical costs reach us$1500- 2000. prolongation of the treatment for a longer time results in increased cost up to us$30 000 or more. poor efficiency of the known methods of treating patients with venous ulcer necessitates the search for new ways and modes of laser therapy (lt) based on a comprehensive approach. application of physical therapy, primarily with the use of lllt, capable of influencing various stages in the pathogenesis of the disease, allows a high therapeutic effect in many cases, while ensuring systemic response of the patient's body with the proper exposure procedure. so, the current study will be conducted to compare the effect of different laser wavelengths on venous ulcers and provide an effective treatment method for patients with venous ulcers with low cost and in short duration.

Eligibility criteria:
inclusion criteria: * all patients approximately the same age (50-60). * all patients had venous leg ulcers just above medial malleolus. the common cause of ulcers for all cases was venous insufficiency. * all patients with conscious. exclusion criteria: * all patients had no diabetes or blood problems. * any immunity disorder affect wound heaing.
exercise training in dystonia

Conditions: Dystonia

Summary: the purpose of this research study is to investigate how the brain and motor behavior changes in individuals with dystonia and other involuntary movement disorders and healthy individuals over time with exercise training.

the study team plan to conduct a randomized prospective, parallel-group, controlled study to examine the effects of exercises in dystonia and other involuntary movement disorders. patients will be randomized to receive either progressive resistance training or a control treatment following the modified fitness protocol. the study team hypothesize that progressive resistance training will result in better outcomes compared to modified fitness protocol. data collect includes 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities (the montreal cognitive assessment, stroop, digit span, hopkins verbal learning test, cowa and animals, and brief test of attention); 4) tests assessing motor abilities including toronto western spasmodic rating scale (twstrs) and burke-fahn-marsden dystonia rating scale (bfmdrs); 5) measures of anxiety and depression (beck depression index, hamilton anxiety and depression rating scales); 5) cervical dystonia related quality of life (cdq-24); 6) visual analog scales-quality of life (vas qol) evaluating of health related quality of life.

Eligibility criteria:
inclusion criteria: patients with dystonia and other involuntary movement disorders will be recruited whose diagnosis will be confirmed by a movement disorders specialist following the criteria recommended by movement disorders society. * patients will be eligible if they are ages 30 to 80 years, * receive stable doses of regular botulinum toxin injections and are on stable doses of oral pharmacological therapy if applicable, and are able to walk for 6 minutes. * age-matched healthy individuals will be recruited for normative data. * all individuals must be capable of providing informed consent and complying with the study related procedures. exclusion criteria: patients will be ineligible if they have a neurological history other than dystonia, have significant arthritis * fail the physical activity readiness questionnaire, have cognitive impairment as indicated by a mini mental state examination score \<23, * already exercising. * as necessitated by the risks of magnetic resonance imaging (mri) or transcranial magnetic stimulation (tms), patients who have any type of implanted electrical device (such as a cardiac pacemaker or a neurostimulator), or a certain type of metallic clip in their body (i.e., an aneurysm clip in the brain) * active seizure disorder are not eligible for participation in the mri or tms portion of the study. * individuals who are claustrophobic will also be excluded from participation. * women who are or might be pregnant and nursing mothers are not eligible. pregnancy tests will be carried out for each female subject of child bearing potential prior to the participation in the study and prior to each follow up visit.
living conditions of patients with diffuse large b-cell lymphoma or follicular lymphoma in the côte d'or region

Conditions: Diffuse Large Cell Diffuse Lymphoma; Follicular Lymphoma

Summary: the development of new diagnostic tools and targeted therapy have significantly improved the management of non-hodgkin's malignant lymphomas and thus their long-term prognosis. however, in the study of improved patient management, survival is not the only measurable indicator and preservation of quality of life is an essential component. in addition, there is little existing data regarding the determinants of quality of life in patients with diffuse large b-cell lymphoma (dlbcl) or follicular lymphoma (fl) in the general population in france.


Eligibility criteria:
inclusion criteria: * patients diagnosed with dlbcl or fl between january 1, 2010 and december 31, 2017, * alive as of january 1, 2021, * updated patient address. exclusion criteria: * other forms of hematologic malignancies at diagnosis, * minors. * person subject to legal protection (curatorship, guardianship) * person subject to a judicial safeguard measure * pregnant, parturient or breastfeeding woman * adults incapable of giving consent
study of nivolumab with or without pazopanib in metastatic or unresectable soft tissue sarcomas

Conditions: Soft Tissue Sarcomas

Summary: this trial will assess whether nivolumab alone or nivolumab combined with pazopanib will be associated with an improvement in progression free survival (pfs) at 6 months

the investigators hypothesize that the nivolumab alone or nivolumab plus pazopanib will be associated with an improvement in progression free survival (pfs) at 6 months compared to historical controls of placebo and pazopanib alone respectively. this is a randomized, phase 2 study of nivolumab alone or nivolumab plus pazopanib in adult (≥ 18 years old) male and female subjects with unresectable or metastatic soft tissue sarcoma either ineligible to receive an anthracycline-based first line treatment or after one prior systemic therapy. up to 33 and 46 subjects will be randomized (1:1) in the nivolumab and nivolumab plus pazopanib cohorts respectively, with a simon two-stage design. preliminary endpoint analysis will be performed when at least 18 subjects in the nivolumab cohort and 16 subjects in the nivolumab plus pazopanib cohort, have completed the first 12 cycles of nivolumab (6 months). accrual duration is expected to be around 2 years.

Eligibility criteria:
inclusion criteria: * histologic diagnosis of metastatic or unresectable soft tissue or bone sarcoma * no prior therapy with nivolumab in either cohorts or with pazopanib in the combination cohort * at least one line of systemic therapy or ineligibility for an anthracycline based chemotherapy * at least 2 distinct measurable metastatic sites * adequate organ and marrow function as defined by initial laboratory tests * life expectancy \> 3 months * stable brain metastases for at least 4 weeks and no steroid dependence exclusion criteria: * autoimmune disease any underlying medical or psychiatric condition, which in the opinion of the investigator, will make the administration of study drugs hazardous or obscure the interpretation of adverse events * concomitant therapy with any non-study immunotherapy regimens, cytotoxic chemotherapy, immunosuppressive agents, other investigation therapies chronic use of systemic corticosteroids greater than prednisone 10 mg daily or its equivalent * women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 5 months after cessation of study drug, or have a positive pregnancy test at baseline, or are pregnant or breastfeeding; * prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical illness.

Keywords: metastatic unresectable anthracycline chemotherapy systemic therapy
coated metal ureteral stent in the treatment of radiation induced ureteral stricture

Conditions: Ureteral Stricture; Hydronephrosis; Radiation Exposure

Summary: a prospective, multicenter and controlled study to observe the efficacy and safety of coated metal ureteral stent in the treatment of radiation induced ureteral stricture.


Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of ureteral stricture and hydronephrosis. 2. previous history of radiation therapy. 3. must be able to tolerate surgery. exclusion criteria: 1. combine with hypertonic neurogenic bladder (except for patients with long-term indwelling catheter). 2. colon resection surgery patients.

Keywords: radiation induced ureteral stricture coated metal ureteral stent safety efficacy
[socrates -acute stroke or transient ischaemic attack treated with aspirin or ticagrelor and patient outcomes]

Conditions: Acute Ischaemic Stroke; Transient Ischaemic Attack

Summary: the primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg \[two 90 mg tablets\] loading dose on day 1 followed by 90 mg twice daily maintenance dose for the remainder of the study) vs acetylsalicylic acid (asa)-aspirin (300 mg \[three 100 mg tablets\] loading dose on day 1 followed by 100 mg once daily maintenance dose for the remainder of the study) for the prevention of major vascular events (composite of stroke, myocardial infarction \[mi\], and death) in patients with acute ischaemic stroke or transient ischaemic attack (tia).


Eligibility criteria:
inclusion criteria: * men or women equal or elder 40 years of age * either acute ischaemic stroke or high-risk tia as defined here and randomisation occurring within 24 hours after onset of symptoms key exclusion criteria: * planned use of antithrombotic therapy in addition to study medication including antiplatelets (eg, open label asa, gpiib/iiia inhibitors, clopidogrel, ticlopidine, prasugrel, dipyridamole, ozagrel, cilostazol) and anticoagulants (eg, warfarin, oral thrombin and factor xa inhibitors, bivalirudin, hirudin, argatroban, unfractionated and low molecular weight heparins). - any history of atrial fibrillation, ventricular aneurysm or suspicion of cardioembolic pathology for tia or stroke. - planned carotid, cerebrovascular, or coronary revascularisation that requires halting study medication within 7 days of randomisation. - receipt of any intravenous or intra-arterial thrombolysis or mechanical thrombectomy within 24 hours prior to randomisation - history of previous symptomatic non-traumatic intracerebral bleed at any time (asymptomatic microbleeds do not qualify), gastrointestinal (gi) bleed within the past 6 months, or major surgery within 30 days.

Keywords: acute ischaemic stroke. transient ischaemic attack.
frequency of vertebrospinal anomalies in patients presenting with anorectal malformations

Conditions: Anorectal Malformations

Summary: to determine the frequency of different vertebrospinal anomalies in patients with arm

106 pediatric patients presenting in department of neonatal and paediatric surgery, the children hospital, pims from date of approval up to 6 months with diagnosis of anorectal malforatioms will be enrolled in the study using non-probability convenience sampling technique. in this way, 106 patients will be included in the study. patient selection will be made in the light of aforementioned exclusion and inclusion criteria of the study. guardians of all patients will be explained about the study and informed consent will be obtained from them. baseline data of enrolled patients will be recorded in the clinical questionnaire after careful history and examination. all patients born in our setup go through initial xray of lumbar spine and sacrum and ultrasound of spine which will be observed. findings in the imaging will be noted in the clinical performa. it will be ensured that data is collected after approval of the synopsis and patient's confidentiality would not be breeched. patients would have the autonomy to withdraw from study whenever they want.

Eligibility criteria:
inclusion criteria: * i.neonates and paediatric patients from age 1 day to 12 years ii.presenting in department of paediatric surgery with anorectal malformation iii.both pre and post op exclusion criteria: * patients who have not consented for further investigations
improving appetite regulation in patients with obesity

Conditions: Weight Loss; Weight Gain Prevention; Obesity

Summary: over 70% of u.s. adults have overweight or obesity. currently, the most efficacious behavioral intervention for obesity is standard behavioral treatment (sbt), often composed of group sessions, calorie goals, and physical activity goals. with this approach, participants often lose 8-10% of the person's baseline weight, and also decrease risk for cardiovascular disease. long-term weight loss, however, is limited; many participants return to baseline weight within five years following treatment. one reason sbt may not create long-term weight loss may be due to treatment components that teach participants to rely on external methods for changing eating decisions (e.g., counting calories, restricting certain foods), rather than internal cues of hunger and satiety. because individuals with obesity report significant challenges with adhering to these cues, augmenting behavioral interventions with appetite self-regulation training may be a solution. thus, the investigator propose to examine the feasibility and acceptability of a 6-month remotely-delivered appetite regulation + lifestyle modification intervention to treat obesity.

aim 1. using a single-arm design, the investigator will examine the feasibility and acceptability of a 6-month, remotely-delivered, appetite self-regulation intervention for weight loss maintenance. aim 2. examine the preliminary efficacy of the intervention on weight maintenance at 4 and 6 months.

Eligibility criteria:
inclusion criteria: * over 18 years of age, * bmi ≥ 25-45 kg/m\^2, * have and regularly use a smartphone, * weight loss of 5% or more within the last 2 years * complete the screening questionnaire exclusion criteria: * have no internet access, * report a medical condition that could jeopardize the person's safety in a weight control program with diet and exercise guidelines * are currently pregnant * are in substance use treatment * are involved in another weight reduction program * have received prior or planned bariatric surgery